Ionis Pharmaceuticals, Inc. and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results